Farmigea

What Farmigea does

Farmigea S.p.A. is an Italian ophthalmology company founded in 1946 and headquartered in Pisa. It researches, produces, and commercializes products covering all major eye pathologies, organized across three product classes: pharmaceutical specialties, medical devices (ophthalmic solutions, gels, ointments, and eyelid wipes), and dietary supplements (Maculife, Vitreolife, Licofor). Its flagship proprietary technology is TS-Polysaccharide (TSP®), a trademarked mucin-mimetic molecule used as a tear film stabilizer in artificial tear formulations, marketed primarily through the HydraMed product family and offered as an active pharmaceutical ingredient for private-label partners. The medical device portfolio spans preservative-free formulations, carbomer-based gels, vitamin A night ointments, and sodium hyaluronate lubricants, with key brands including HydraMed (and Forte/Night/Night Sensitive/Wipes variants), Cellusan (and Cellusan Light), EyeGel (and EyeGel Plus), Hye, Hy-Light, and Pure.

The business operates two distinct revenue engines. The first is a branded portfolio sold through pharmacy distribution and healthcare provider channels across multiple European markets, with marketing authorizations secured in Italy, Germany, Spain, Poland, Portugal, and the United Kingdom. The second is a Contract Development and Manufacturing Organization (CDMO) and private-label service through which Farmigea develops, formulates, registers, and manufactures ophthalmic products for third-party pharmaceutical companies, leveraging its AIFA GMP authorization for sterile topical ophthalmic forms (including hormone-based, biological origin, and Investigational Medicinal Products) and its UNI EN ISO 9001:2015 and UNI CEI ISO 13485:2016 certifications.

Farmigea monetizes through one-time product sales across both channels, with the CDMO layer additionally generating professional services revenue from formulation development, regulatory filing, and contract manufacturing engagements. The company markets itself as a "complete partner in ophthalmology" and distributes an international product catalog of branded pharmaceuticals, medical devices, and supplements. Its corporate website operates in five languages (Italian, English, Spanish, French, German), and it maintains corporate social profiles across LinkedIn, X/Twitter, Facebook, and Instagram. The company is privately held with €10,000,000 in registered share capital, 101-250 employees, and no disclosed external institutional investors, M&A activity, or capital raises. Its brand was inscribed in Italy's Special Register of Historic Brands of National Interest in 2021, and it is currently deploying co-funded EU/regional development grants (Toscana FESR, PON) to expand internationalization, R&D, and digital operations.

Name

Farmigea

Legal name

Farmigea S.p.A.

Website

https://farmigea.it

Company type

Private

Founded year

1946

Operating status

Operating

Headcount range

101–250 employees

Short description

Farmigea is a privately held Italian ophthalmology company (founded 1946, Pisa) that develops, manufactures, and distributes branded pharmaceuticals, medical devices, and dietary supplements for eye conditions, and provides CDMO/private-label services to third-party pharmaceutical firms across European markets.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic pharmaceuticals
• Medical devices
• Contract manufacturing
• Dry eye treatment
• Dietary supplements

Headquarters

HQ city

Pisa

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Production and commercialization of pharmaceutical specialties (Farmaci) covering all eye pathologies for the international market.
2. Medical Devices: Production and sale of medical devices for ophthalmic use including eye drops, solutions, and gels.
3. Dietary Supplements: Sale of nutritional supplements (Integratori) for eye health including Maculife, Vitreolife, and Licofor.
4. CDMO Services: Contract development and manufacturing services for third-party pharmaceutical companies seeking ophthalmic product development and production. Includes private label product customization.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Farmigea researches, manufactures, and commercializes ophthalmic pharmaceutical specialties, medical devices (eye drops, ophthalmic solutions, gels, ointments, eyelid wipes), and dietary supplements covering all eye pathologies. The company also operates as a Contract Development and Manufacturing Organization (CDMO), providing private label and contract manufacturing services to third-party pharmaceutical companies for sterile topical ophthalmic products.

Product overview

Farmigea is an Italian ophthalmology company specializing since 1946 in research, production, and commercialization of ophthalmic products covering all eye pathologies. The company operates as both a brand owner with its own product portfolio and as a Contract Development and Manufacturing Organization (CDMO) for third parties. The product portfolio consists of Medical Devices (ophthalmic solutions, gels, ointments, and wipes), Dietary Supplements (Maculife, Vitreolife, Licofor), and Pharmaceutical Products. Key product lines include the HydraMed family (HydraMed, HydraMed Forte, HydraMed Night, HydraMed Night Sensitive, HydraMed Wipes), the Cellusan line (Cellusan, Cellusan Light), EyeGel products (EyeGel, EyeGel Plus), Hye, Hy-Light, and Pure. The company also offers Private Label/contract manufacturing options including TS-Polysaccharide formulations at various concentrations, Hyaluronic Acid products, and pharmaceutical eye drops (Ofloxacin, Diclofenac, Ketotifene, Tobramycin).

Differentiator

Problem solved

Functional benefit

Products and services

• HydraMed Moisturizing, lubricant and normalizing ophthalmic solution containing TS-Polysaccharide (TSP) and high-molecular weight Sodium Hyaluronate obtained by biotechnological synthesis. Provides synergistic normalizing action on the corneo-conjunctival surface and protects from irritation due to environmental factors, visual fatigue, or mechanical factors.
• HydraMed Forte Intensive lubrication and protection ophthalmic solution for the ocular surface. Contains TS-Polysaccharide and high-molecular weight Sodium Hyaluronate with calibrated concentration to ensure lubrication even in cases of more intense discomfort.
• Hye Intensive relief ophthalmic solution with high molecular weight Sodium Hyaluronate. The lubricant, moisturizing and protective qualities relieve irritation, dryness, burning and foreign body sensation due to environmental elements or ocular surgery.
• Hy-Light Moisturizing and lubricant Sodium Hyaluronate solution. Particularly suitable for sensitive eyes, for frequent and prolonged use and during contact lens wear (preservative-free formulations).
• Cellusan Lubricating eye drops for long lasting and soothing relief from moderate to severe dry eyes. Provides protection against burning, irritation and discomfort associated with ocular dryness or exposure to environmental factors. Preservative-free and suitable for use with contact lenses.
• Cellusan Light Lubricating eye drops providing long lasting and soothing relief from moderate to severe dry eyes with a lighter formulation. Offers protection against burning, irritation and discomfort. Preservative-free and suitable for contact lens use.
• EyeGel

Quantifiable outcome

• 36 months shelf life for TS-Polysaccharide products

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered minor.

• METIDEminorStrategic or Co-development Partner · 1 January 2025Project financed under the REGIONAL PROGRAMME TOSCANA FESR 2021-2027, Action 1.3.1 'Support for export-oriented SMEs', Internationalization 2025 call for proposals. Farmigea received funding to support internationalization activities.
• FAR012024minorStrategic or Co-development Partner · 1 January 2024Project funded under the regional Tuscany FESR 2021-2027 programme, Action 1.1.4 'Research and Development for Enterprises', Call No.2: R&D Projects for SMEs and Midcaps.
• WAter Treatment of high Surfactants concentrations by Oxigen and Non thermal plasmaminorStrategic or Co-development PartnerProject funded under POR FESR Toscana 2014-2020, Action 1.1.5 Sub. A1, Call No.2 – Research and development projects for SMEs. Research project focused on water treatment technologies.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Alcon: World's largest eye-care company spanning surgical, vision care, and ophthalmic pharmaceuticals. Its Systane artificial-tears franchise directly competes with Farmigea's dry-eye portfolio and sets the benchmark for EU pharmacy-channel pricing and promotion.
• Bausch + Lomb: Global ophthalmology incumbent with leading artificial-tears brands (Soothe, Artelac) and a broad Rx ophthalmics portfolio. Overlaps directly with Farmigea's HydraMed, Cellusan, and EyeGel ranges, but at vastly larger commercial and R&D scale.
• Allergan (AbbVie): Owner of Restasis and other ophthalmic brands within AbbVie's broader immunology/aesthetics portfolio. Competes in the same dry-eye and ocular-surface categories where Farmigea is positioned and exerts substantial pricing and detailing pressure on European pharmacies.

Direct peers

• Théa: Privately-held French ophthalmology specialty company focused on prescription and OTC eye-care products, with strong presence across Europe. Highly comparable to Farmigea in being a family-owned, mid-sized European ophthalmic specialist with branded and CDMO-style offerings.
• Santen Pharmaceutical: Japanese-headquartered specialty ophthalmology company with a global footprint focused on prescription ophthalmics (glaucoma, dry eye, retinal). Comparable as a pure-play ophthalmology specialist targeting the same prescriber base and pharmacy channels as Farmigea.

Emerging players

• Nicox: France-based ophthalmology company developing and licensing prescription eye-care therapeutics, including partnerships and CDMO arrangements. Comparable as a smaller specialty ophthalmology company commercializing through licensing and partnership models, similar to Farmigea's private-label/CDMO channel.
• Novaliq: Germany-based specialty ophthalmology company developing water-free and preservative-free eye-drop technologies for dry eye and ocular surface disease. Comparable as a European mid-cap focused on differentiated formulation science in the same dry-eye category Farmigea serves.
• Oyster Point Pharma: US-based specialty ophthalmology company focused on dry-eye disease therapeutics. Comparable as a pure-play dry-eye specialist whose category positioning and pipeline economics mirror those Farmigea targets with its HydraMed/Cellusan franchises.

Regional players

• Sooft Italia: Italian ophthalmology company headquartered in Italy with a portfolio of ocular-surface and dry-eye products. Closely comparable to Farmigea as a domestic Italian competitor with overlapping products (artificial tears, ophthalmic nutraceuticals) and a similar specialty-pharma profile.
• AFT Pharmaceuticals: New Zealand-listed specialty pharmaceutical company with a growing ophthalmology and consumer eye-care portfolio distributed via licensing partners. Comparable as a mid-sized specialty pharma using partner-driven distribution and licensing, akin to Farmigea's private-label and CDMO model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Farmigea
• Facebookfacebook.com/Farmigea
• LinkedInlinkedin.com/company/farmigea
• Instagraminstagram.com/farmigea_

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmigea